CHICAGO — The Meals and Drug Administration’s prime oncologist reiterated that the company doesn’t need drugmakers making use of for approval with information from trials solely run in a single nation comparable to China, however as a substitute desires to see firms conducting research the world over.
The feedback by Richard Pazdur, director of the FDA’s Oncology Heart of Excellence, got here as extra drugmakers report information from China, with Miami-based Summit Therapeutics earlier this week saying that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung most cancers research in China.
It’s not a blanket coverage, and the company would assess every firm’s submission to see how relevant the information are to the U.S. inhabitants, however normally, “I’m professional multi-regional trials,” Pazdur mentioned Friday at STAT@ASCO, STAT’s occasion on the American Society of Medical Oncology annual assembly.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans